Monitor and track your COPD and asthma using your smartphone
Worldwide, asthma affects around 339 million people1, and 251 million people have chronic obstructive pulmonary disease (COPD)2. Asthma and COPD cannot be cured; however appropriate management can help relieve symptoms, improve quality of life and reduce the risk of death.
ResApp has developed smartphone-based machine learning algorithms that accurately identify acute exacerbations in patients with asthma or COPD.
1. The Global Asthma Report 2018, Global Asthma Network
2. The Global Burden of Disease Study, Institute for Health Metrics and Evaluation
Scientific Presentations & Publications
Sharan RV, Abeyratne UR, Swarnkar VR, Claxton S, Hukins C, Porter P, Predicting spirometry readings using cough sound features and regression, Physiological Measurement 39(9), 2018.
ResApp Health Limited
ABN 51 094 468 318
Level 12, 100 Creek St, Brisbane, QLD 4000
© 2020 ResApp Health Limited. All rights reserved. US Patent No. 10,098,569, Australian Patent No. 2013239327, Japanese Patent No. 6,435,257 and Patents Pending. ResApp Health®, the ResApp Health logo and ResAppDx® are registered trademarks of ResApp Health Limited in the United States and other countries. ResAppDx is not available for sale in the United States.